GHRP-2

GHRP-2 Molecular Structure & Chemical Properties

Growth Hormone-Releasing Peptide-2 (GHRP-2) represents one of the most extensively studied growth hormone secretagogues in preclinical and clinical research, with investigations spanning over three decades since its development in the 1980s. Also known as pralmorelin, this synthetic hexapeptide was the first growth hormone secretagogue to receive regulatory approval for clinical use, specifically as a diagnostic agent for growth hormone deficiency in Japan. Unlike its predecessors, GHRP-2 demonstrates exceptional oral bioavailability and dose-dependent growth hormone release, making it a valuable research tool for understanding the ghrelin receptor system and its physiological roles.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s structure incorporates multiple D-amino acids including D-alanine, D-2-naphthylalanine, and D-phenylalanine, which provide enhanced resistance to enzymatic degradation and contribute to its oral bioavailability.

GHRP-2 Mechanism of Action

GHRP-2 functions as a potent agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor, stimulating growth hormone release through multiple coordinated pathways. Current research indicates that ghrelin receptor activation serves as the primary mechanism, with downstream effects involving both pituitary and hypothalamic targets to produce dose-dependent growth hormone secretion.

Primary Cellular Pathways

GHS-R1a Receptor Activation – Growth Hormone Release

GHRP-2 binds to and activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering a cascade of intracellular signaling events[1]. This receptor activation leads to:

• Enhanced calcium influx through voltage-gated calcium channels
• Increased intracellular calcium release from thapsigargin-sensitive stores
• Activation of protein kinase C (PKC) and protein kinase A (PKA) pathways
• Direct stimulation of growth hormone granule exocytosis

Studies using human pituitary somatotrophinoma cells demonstrated that GHRP-2 stimulates phosphatidylinositol turnover, a key second messenger system leading to PKC activation and calcium mobilization[2].

Hypothalamic GHRH Pathway Modulation

Research indicates GHRP-2 peptide also acts at the hypothalamic level to enhance growth hormone-releasing hormone (GHRH) secretion[3]. This dual mechanism includes:

• Stimulation of GHRH neurons in the arcuate nucleus
• Enhancement of natural GHRH pulsatile release patterns
• Synergistic interaction when combined with exogenous GHRH administration
• Modulation of somatostatin inhibitory pathways

Clinical studies have demonstrated marked synergy between GHRP-2 and GHRH, producing growth hormone responses greater than either peptide alone.

ACTH and Cortisol Pathway Interaction

GHRP-2 demonstrates mild stimulatory effects on the hypothalamic-pituitary-adrenal axis, particularly at higher doses[4]. These effects include:

• Moderate increase in ACTH secretion from anterior pituitary corticotrophs
• Secondary elevation of cortisol levels in dose-dependent manner
• Activation of both PKA and PKC pathways in pituitary cells
• No significant effect on prolactin, TSH, or gonadotropin release

Appetite and Metabolic Signaling

As a ghrelin receptor agonist, GHRP-2 peptide influences appetite regulation and metabolic processes[5]:

• Stimulation of appetite centers in the hypothalamus
• Increased food intake in human clinical studies
• Enhanced gastric motility and digestive processes
• Modulation of glucose metabolism and insulin sensitivity

Cardiovascular and Cytoprotective Effects

Emerging research suggests GHRP-2 may provide cardiovascular benefits through GHS-R1a activation in cardiac tissue[6]:

• Potential cardioprotective effects against ischemia-reperfusion injury
• Positive inotropic effects on cardiac contractility
• Anti-apoptotic properties in cardiomyocytes under stress conditions
• Possible applications in dilated cardiomyopathy research

GHRP-2 Research Applications & Key Findings

Growth Hormone Diagnostic Applications

Clinical Assessment of Growth Hormone Deficiency

GHRP-2 peptide has received regulatory approval in Japan as a diagnostic agent for growth hormone deficiency, representing its most established clinical application[7]. Key research findings include:

• Reliable stimulation of growth hormone release in healthy individuals regardless of age, gender, or obesity status
• Clear differentiation between normal and deficient growth hormone responses
• Superior diagnostic sensitivity compared to insulin tolerance testing in some populations
• Minimal side effects during diagnostic procedures

Studies in children with suspected growth hormone deficiency demonstrated that GHRP-2 administration (1 mcg/kg intravenously) consistently provoked measurable growth hormone responses[8].

Comparative Efficacy in Growth Hormone Disorders

Research in patients with confirmed growth hormone deficiency showed differential responses to GHRP-2 depending on the underlying pathophysiology[9]:

• Enhanced responses in patients with hypothalamic dysfunction compared to pituitary lesions
• Maintained efficacy in patients with mutated GHRH receptors, suggesting GHRH-independent mechanisms
• Variable responses in idiopathic short stature populations
• Preserved function in aging populations with declining natural growth hormone secretion

Pharmacokinetic and Pharmacodynamic Research

Human Bioavailability Studies

Clinical pharmacokinetic investigations have characterized GHRP-2’s absorption and distribution patterns[10]. Important findings include:

• Oral bioavailability of approximately 0.3% compared to intravenous administration
• Peak plasma concentrations occurring 15-60 minutes after oral dosing
• Biexponential elimination with terminal half-life of 0.55 hours
• Effective plasma clearance of 0.66 L/h/kg in pediatric populations

Despite rapid clearance, biological effects persist for 2-4 hours, suggesting either tissue retention or persistent downstream signaling.

Dose-Response Relationships

Multiple dose-ranging studies have established clear dose-response relationships for GHRP-2[11]:

• Threshold doses as low as 0.1 mcg/kg intravenously elicit measurable growth hormone responses
• Optimal responses typically achieved at 1-3 mcg/kg for diagnostic applications
• Oral dosing requires 100-300 mcg/kg to achieve comparable effects to 1 mcg/kg intravenously
• Partial desensitization observed with continuous infusion but not intermittent dosing

Appetite and Metabolic Research

Food Intake Studies

Clinical research has demonstrated GHRP-2’s appetite-stimulating properties in human subjects[12]. Key findings include:

• 35.9% increase in food intake during acute subcutaneous infusion studies
• Consistent appetite enhancement across all study participants
• Effects similar to those observed with natural ghrelin administration
• No alteration in macronutrient preferences during enhanced feeding

These studies provide valuable insights into ghrelin receptor function and appetite regulation mechanisms.

Body Composition Effects

Long-term administration studies in growth hormone-deficient populations have examined body composition changes[13]:

• Increased lean body mass in children receiving chronic oral GHRP-2
• Modest improvements in bone density markers in some studies
• Enhanced growth velocity in pediatric populations with growth hormone deficiency
• Variable effects on fat mass depending on underlying metabolic status

Specialized Clinical Research

Critical Illness Applications

Research in intensive care settings has explored GHRP-2’s effects during critical illness[14]:

• Preservation of growth hormone responsiveness during prolonged critical illness
• Potential metabolic benefits in catabolic states
• Enhanced protein synthesis markers in some studies
• Improved outcomes when combined with GHRH in critical care populations

Aging and Sarcopenia Research

Investigations in elderly populations have examined GHRP-2’s effects on age-related growth hormone decline[15]:

• Maintained growth hormone responsiveness in healthy elderly subjects
• Potential benefits for muscle mass preservation in aging populations
• Enhanced sleep quality and nocturnal growth hormone secretion
• Ongoing research into applications for age-related frailty syndromes

GHRP-2 Pharmacokinetics & Metabolism

Absorption & Distribution

GHRP-2 demonstrates unique pharmacokinetic properties among peptide therapeutics, with confirmed oral bioavailability despite being a hexapeptide[16]. Following administration in human studies:

• Rapid absorption occurs within 15-30 minutes via multiple routes including oral, subcutaneous, and intravenous
• Peak plasma concentrations achieved at 15-60 minutes depending on route of administration
• Distribution volume of approximately 0.32 L/kg suggesting limited tissue penetration
• Effective oral bioavailability of 0.3% relative to intravenous administration

Clinical studies using radiolabeled GHRP-2 have demonstrated rapid distribution to target tissues, with preferential uptake in pituitary and hypothalamic regions expressing GHS-R1a receptors[17].

Metabolism & Elimination

The metabolic fate of GHRP-2 follows typical peptide degradation pathways, though specific metabolites remain incompletely characterized[18]:

• Plasma half-life of 30-60 minutes in human studies
• Biexponential elimination kinetics with rapid initial distribution phase
• Primary metabolism likely through peptidase activity and amino acid recycling
• No evidence of active metabolites contributing to biological effects

A notable pharmacokinetic paradox exists: despite rapid plasma clearance, growth hormone elevations persist for 2-4 hours, suggesting either receptor-mediated prolonged signaling or tissue retention mechanisms.

Excretion Pathways

Limited data on GHRP-2 excretion pathways indicates[19]:

• Renal elimination of peptide fragments following enzymatic breakdown
• No evidence of unchanged peptide excretion in urine
• Hepatic metabolism may contribute to clearance through first-pass effects
• No accumulation observed in chronic dosing studies

The rapid elimination combined with sustained biological effects makes GHRP-2 suitable for multiple daily dosing regimens without accumulation concerns.

GHRP-2 Research Protocols & Administration

Dosing in Published Research

Clinical investigations have employed diverse GHRP-2 dosing protocols depending on study objectives and population characteristics:

• Diagnostic applications: 1-3 mcg/kg intravenously as single bolus doses
• Oral administration studies: 100-300 mcg/kg for growth hormone stimulation testing
• Chronic therapy research: 1-2 mcg/kg subcutaneously twice daily in pediatric studies
• Appetite research: 1 mcg/kg/hour continuous subcutaneous infusion protocols

Important: These are experimental and diagnostic doses used in clinical research protocols and cannot be extrapolated to other species or applications due to significant differences in receptor sensitivity, metabolism, pharmacokinetics, and regulatory approval status. Species-specific factors and individual patient characteristics profoundly influence both efficacy and safety profiles.

Administration Routes in Research

Multiple delivery methods have been validated in clinical research:

• Intravenous injection – Standard route for diagnostic applications; rapid onset and predictable pharmacokinetics
• Subcutaneous injection – Used in chronic administration studies; consistent absorption with minimal injection site reactions
• Oral administration – Unique among peptides; requires higher doses but demonstrates clinical activity
• Intranasal delivery – Investigated in pediatric populations; potential for improved patient compliance
• Continuous infusion – Used in research settings to maintain steady plasma levels

Model Organisms and Study Populations

GHRP-2 has been studied across diverse research contexts:

• Human clinical trials – Healthy volunteers, growth hormone-deficient children and adults, elderly populations
• Pediatric populations – Children with idiopathic short stature, confirmed growth hormone deficiency
• Adult populations – Healthy volunteers, critical illness patients, aging research subjects
• Diagnostic applications – Patients undergoing evaluation for suspected growth hormone disorders
• Special populations – Intensive care patients, elderly subjects, obesity research

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite GHRP-2’s unique position as the only growth hormone secretagogue with regulatory approval for diagnostic use, significant limitations constrain its broader clinical application and research utility.

Limited Therapeutic Trial Data

The most significant limitation is the absence of large-scale therapeutic efficacy trials:

• No published Phase III trials for therapeutic applications beyond diagnostic use
• Limited long-term safety data in healthy populations
• Therapeutic efficacy data primarily from small-scale studies or case series
• Optimal therapeutic dosing regimens not established through controlled trials

Mechanistic Understanding Gaps

Key aspects of GHRP-2’s mechanism and physiological effects require further investigation:

• Cardiovascular effects incompletely characterized despite promising preclinical data
• Relationship between growth hormone-dependent and independent effects unclear
• Long-term effects on natural growth hormone axis regulation unknown
• Potential for receptor desensitization with chronic use inadequately studied

Long-Term Safety Considerations

Critical safety questions remain unanswered for extended use scenarios:

• Chronic administration effects beyond several months inadequately studied
• Cardiovascular safety profile in populations with existing cardiac disease unknown
• Potential interactions with other medications or hormonal therapies uncharacterized
• Effects on glucose metabolism and insulin sensitivity in diabetic populations unstudied

Regulatory & Competitive Sport Status

FDA Position

GHRP-2 holds a unique regulatory position in the United States:

• Not approved for therapeutic use in the United States
• Available for research purposes through investigational protocols
• Classified as an investigational drug requiring proper research oversight
• Pralmorelin approved in Japan for diagnostic assessment of growth hormone deficiency

The FDA has not approved GHRP-2 for any therapeutic indications, limiting its availability to research applications under appropriate institutional review board oversight.

WADA Prohibition

The World Anti-Doping Agency classifies GHRP-2 as a prohibited substance:

• Listed under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)
• Prohibited at all times (in and out of competition)
• No Therapeutic Use Exemptions available for athletic populations
• Detection methods under development for anti-doping testing

WADA’s prohibition reflects concerns about potential performance-enhancing effects through growth hormone pathway activation.

Research Classification: GHRP-2 is available for laboratory research use and approved diagnostic applications in specific jurisdictions. It is not intended for therapeutic use outside approved indications or without appropriate medical supervision. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Sawada, H., Yamaguchi, H., Shimbara, T., Toshinai, K., Mondal, M.S., Date, Y., Murakami, N., Miyazato, M., Kangawa, K., & Nakazato, M. (2006). Effects of ghrelin on food intake and neuroendocrine function in sheep. Domestic Animal Endocrinology, 31(3), 155-173. PubMed
   
2. Adams, E.F., Petersen, B., Lei, T., Buchfelder, M., & Fahlbusch, R. (1995). Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. Journal of Molecular Endocrinology, 14(1), 135-145. PubMed
   
3. Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. European Journal of Endocrinology, 136(5), 445-460. PubMed
   
4. Tanaka, M., Hayashida, Y., Iguchi, T., Nakao, N., Nakai, N., & Nakashima, K. (2009). Growth hormone-releasing peptide-2 stimulates secretion and synthesis of adrenocorticotropic hormone in mouse pituitary. Neuroendocrinology, 90(3), 232-241. PubMed
   
5. Laferrère, B., Abraham, C., Russell, C.D., & Bowers, C.Y. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism, 90(2), 611-614. PubMed
   
6. Granado, M., Priego, T., Martín, A.I., Villanúa, M.A., & López-Calderón, A. (2005). Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American Journal of Physiology-Endocrinology and Metabolism, 288(3), E486-E492. PubMed
   
7. Editorial. (2004). Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R&D, 5(4), 236-239. PubMed
   
8. Pihoker, C., Kearns, G.L., French, D., & Bowers, C.Y. (1998). Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: A phase I study in children. Journal of Clinical Endocrinology & Metabolism, 83(4), 1168-1172. PubMed
   
9. Gondo, R.G., Aguiar-Oliveira, M.H., Hayashida, C.Y., Toledo, S.P., Abelin, N., Levine, M.A., Bowers, C.Y., Souza, A.H., Pereira, R.M., Santos, N.L., & Salvatori, R. (2001). Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. Journal of Clinical Endocrinology & Metabolism, 86(7), 3279-3283. PubMed
   
10. Pihoker, C., Kearns, G.L., French, D., & Bowers, C.Y. (1998). Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: A phase I study in children. Journal of Clinical Endocrinology & Metabolism, 83(4), 1168-1172. PubMed
    
11. Bowers, C.Y., Alster, D.K., & Frentz, J.M. (1992). The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. Journal of Clinical Endocrinology & Metabolism, 74(2), 292-298. PubMed
    
12. Laferrère, B., Abraham, C., Russell, C.D., & Bowers, C.Y. (2005). Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism, 90(2), 611-614. PubMed
    
13. Mericq, V., Cassorla, F., Bowers, C.Y., Avila, A., Gonen, B., & Merriam, G. (2003). Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in GH deficient children. Journal of Pediatric Endocrinology & Metabolism, 16(7), 981-985. PubMed
    
14. Van den Berghe, G., de Zegher, F., Veldhuis, J.D., Wouters, P., Awouters, M., Verbruggen, W., Schetz, M., Verwaest, C., Lauwers, P., Bouillon, R., & Bowers, C.Y. (1997). The somatotropic axis in critical illness: Effect of continuous GHRH and GHRP-2 infusion. Journal of Clinical Endocrinology & Metabolism, 82(2), 590-599. PubMed
    
15. Veldhuis, J.D., Keenan, D.M., & Bowers, C.Y. (2009). Preservation of GHRH and GHRP-2 efficacy in young men with experimentally induced hypogonadism. European Journal of Endocrinology, 161(2), 293-300. PubMed
    
16. Bowers, C.Y., Alster, D.K., & Frentz, J.M. (1992). The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. Journal of Clinical Endocrinology & Metabolism, 74(2), 292-298. PubMed
    
17. Hashizume, T., Takahashi, Y., Numata, M., Sasaki, K., Nakatani, Y., & Kanematsu, S. (2000). The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine. Animal Science Journal, 71(3), 195-200.
18. Wu, R., Zhou, M., Wang, P., & Liu, J. (2015). Synthesis of mono-PEGylated growth hormone releasing peptide-2 and investigation of its biological activity. Chemical Research in Chinese Universities, 31(6), 1000-1006. PubMed
    
19. Jordan, R.A., Kagan, N., & Scatina, J. (1996). Metabolism and excretion of a growth hormone releasing peptide, GPA-748 or GHRP-2, in rats and monkeys following intravenous, subcutaneous and oral administration. Xenobiotica, 26(10), 1085-1095.

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. GHRP-2 is intended for laboratory research use only.